Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: A study of thirteen antibodies
To identify the most accurate and useful panel to diagnose mesothelioma, we immunostained sections from 112 mesotheliomas, 18 adenocarcinomas, and 11 reactive pleural specimens with 13 antibodies. Positive results for mesotheliomas, adenocarcinomas, and reactive pleura, respectively, were CAM5.2, 11...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical pathology 2001-08, Vol.116 (2), p.253-262 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 262 |
|---|---|
| container_issue | 2 |
| container_start_page | 253 |
| container_title | American journal of clinical pathology |
| container_volume | 116 |
| creator | ROBERTS, Fiona HARPER, Christina M DOWNIE, Ian BURNETT, Rodney A |
| description | To identify the most accurate and useful panel to diagnose mesothelioma, we immunostained sections from 112 mesotheliomas, 18 adenocarcinomas, and 11 reactive pleural specimens with 13 antibodies. Positive results for mesotheliomas, adenocarcinomas, and reactive pleura, respectively, were CAM5.2, 111, 18, and 11; vimentin, 30, 3, and 3; HBME-1, 75, 10, and 8; thrombomodulin, 31, 2, and 2; calretinin, 43, 6, and 11; and CD44H, 68, 10, and 4. Positive results for adenocarcinoma markers in mesotheliomas and adenocarcinomas, respectively, were carcinoembryonic antigen, 1 and 15; LeuM1, 7 and 9; and Ber-EP4, 5 and 12. All reactive pleura were negative. Positive results for markers to help distinguish mesothelioma from reactive pleura in mesotheliomas, adenocarcinomas, and reactive pleura, respectively, were epithelial membrane antigen, 76, 17, and 6; p53, 78, 16, and 9; P-170 glycoprotein, 37, 4, and 2; and platelet-derived growth factor receptor beta, 31, 1, and 2. The differential diagnosis of mesothelioma from adenocarcinoma is based on negative markers. Individual mesothelial markers are of low sensitivity and specificity for mesothelioma. However, diagnostic accuracy is improved by the use of antibody panels. To date there are no antibodies that help distinguish mesothelioma from reactive pleura. |
| doi_str_mv | 10.1309/XL6K-8E62-9FLD-V8Q8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71065522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71065522</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-6d39c5b7c9538031a239bbd0818763c45b3b996d23b5546200020a7d9ecef42a3</originalsourceid><addsrcrecordid>eNpFkEtP3TAQRq2qCC6UX1Cp8qbdBfzIw2aHKC9xJYREq-6sie0QV35A7Czurj-9ibgSq1nM-b7RHIS-UnJGOZHnf7btQyWuW1bJm-3P6rd4Ep_QhsqaV13H2Ge0IYQsS9rxI3Sc819CKBOkPkRHlNZCkI5v0L_7EOaYRpdL0qMNToPHEMHvsss4F-c9HiFjwN4FV6zBU_IWu4jLaLFx8BLTSqYBB_DuJUIsONiclrV3KcAFvlxqZrNbkTK6qVgblwvF9ck4m7-ggwF8tqf7eYJ-3Vw_X91V28fb-6vLbaWZoKVqDZe66TstGy4Ip8C47HtDBBVdy3Xd9LyXsjWM901Tt2x9nUBnpNV2qBnwE_Tjvfd1Sm-zzUUFl7X1HqJNc1YdJW3TMLaA_B3UU8p5soN6nVyAaacoUat4tYpXq3i1iler-CX1bV8_98Gaj8ze9AJ83wOQF8fDBFG7_MHVREraUP4fxPSOVw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71065522</pqid></control><display><type>article</type><title>Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: A study of thirteen antibodies</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>ROBERTS, Fiona ; HARPER, Christina M ; DOWNIE, Ian ; BURNETT, Rodney A</creator><creatorcontrib>ROBERTS, Fiona ; HARPER, Christina M ; DOWNIE, Ian ; BURNETT, Rodney A</creatorcontrib><description>To identify the most accurate and useful panel to diagnose mesothelioma, we immunostained sections from 112 mesotheliomas, 18 adenocarcinomas, and 11 reactive pleural specimens with 13 antibodies. Positive results for mesotheliomas, adenocarcinomas, and reactive pleura, respectively, were CAM5.2, 111, 18, and 11; vimentin, 30, 3, and 3; HBME-1, 75, 10, and 8; thrombomodulin, 31, 2, and 2; calretinin, 43, 6, and 11; and CD44H, 68, 10, and 4. Positive results for adenocarcinoma markers in mesotheliomas and adenocarcinomas, respectively, were carcinoembryonic antigen, 1 and 15; LeuM1, 7 and 9; and Ber-EP4, 5 and 12. All reactive pleura were negative. Positive results for markers to help distinguish mesothelioma from reactive pleura in mesotheliomas, adenocarcinomas, and reactive pleura, respectively, were epithelial membrane antigen, 76, 17, and 6; p53, 78, 16, and 9; P-170 glycoprotein, 37, 4, and 2; and platelet-derived growth factor receptor beta, 31, 1, and 2. The differential diagnosis of mesothelioma from adenocarcinoma is based on negative markers. Individual mesothelial markers are of low sensitivity and specificity for mesothelioma. However, diagnostic accuracy is improved by the use of antibody panels. To date there are no antibodies that help distinguish mesothelioma from reactive pleura.</description><identifier>ISSN: 0002-9173</identifier><identifier>EISSN: 1943-7722</identifier><identifier>DOI: 10.1309/XL6K-8E62-9FLD-V8Q8</identifier><identifier>PMID: 11488073</identifier><identifier>CODEN: AJCPAI</identifier><language>eng</language><publisher>Chicago, IL: American Society of Clinical Pathologists</publisher><subject>Adenocarcinoma - chemistry ; Adenocarcinoma - diagnosis ; Antigens, Surface - analysis ; Biological and medical sciences ; Biomarkers ; Biomarkers, Tumor - analysis ; Calbindin 2 ; Carcinoembryonic Antigen - analysis ; Diagnosis, Differential ; Glycoproteins - analysis ; Humans ; Hyaluronan Receptors - analysis ; Immunohistochemistry ; Investigative techniques, diagnostic techniques (general aspects) ; Keratins - analysis ; Lewis X Antigen - analysis ; Medical sciences ; Mesothelioma - chemistry ; Mesothelioma - diagnosis ; Miscellaneous. Technology ; Mucin-1 - analysis ; Neoplasm Metastasis ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Peritoneal Neoplasms - chemistry ; Peritoneal Neoplasms - diagnosis ; Pleural Neoplasms - chemistry ; Pleural Neoplasms - diagnosis ; Receptor, Platelet-Derived Growth Factor beta - analysis ; S100 Calcium Binding Protein G - analysis ; Thrombomodulin - analysis ; Tumor Suppressor Protein p53 - analysis ; Vimentin - analysis</subject><ispartof>American journal of clinical pathology, 2001-08, Vol.116 (2), p.253-262</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c281t-6d39c5b7c9538031a239bbd0818763c45b3b996d23b5546200020a7d9ecef42a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14099151$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11488073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ROBERTS, Fiona</creatorcontrib><creatorcontrib>HARPER, Christina M</creatorcontrib><creatorcontrib>DOWNIE, Ian</creatorcontrib><creatorcontrib>BURNETT, Rodney A</creatorcontrib><title>Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: A study of thirteen antibodies</title><title>American journal of clinical pathology</title><addtitle>Am J Clin Pathol</addtitle><description>To identify the most accurate and useful panel to diagnose mesothelioma, we immunostained sections from 112 mesotheliomas, 18 adenocarcinomas, and 11 reactive pleural specimens with 13 antibodies. Positive results for mesotheliomas, adenocarcinomas, and reactive pleura, respectively, were CAM5.2, 111, 18, and 11; vimentin, 30, 3, and 3; HBME-1, 75, 10, and 8; thrombomodulin, 31, 2, and 2; calretinin, 43, 6, and 11; and CD44H, 68, 10, and 4. Positive results for adenocarcinoma markers in mesotheliomas and adenocarcinomas, respectively, were carcinoembryonic antigen, 1 and 15; LeuM1, 7 and 9; and Ber-EP4, 5 and 12. All reactive pleura were negative. Positive results for markers to help distinguish mesothelioma from reactive pleura in mesotheliomas, adenocarcinomas, and reactive pleura, respectively, were epithelial membrane antigen, 76, 17, and 6; p53, 78, 16, and 9; P-170 glycoprotein, 37, 4, and 2; and platelet-derived growth factor receptor beta, 31, 1, and 2. The differential diagnosis of mesothelioma from adenocarcinoma is based on negative markers. Individual mesothelial markers are of low sensitivity and specificity for mesothelioma. However, diagnostic accuracy is improved by the use of antibody panels. To date there are no antibodies that help distinguish mesothelioma from reactive pleura.</description><subject>Adenocarcinoma - chemistry</subject><subject>Adenocarcinoma - diagnosis</subject><subject>Antigens, Surface - analysis</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Calbindin 2</subject><subject>Carcinoembryonic Antigen - analysis</subject><subject>Diagnosis, Differential</subject><subject>Glycoproteins - analysis</subject><subject>Humans</subject><subject>Hyaluronan Receptors - analysis</subject><subject>Immunohistochemistry</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Keratins - analysis</subject><subject>Lewis X Antigen - analysis</subject><subject>Medical sciences</subject><subject>Mesothelioma - chemistry</subject><subject>Mesothelioma - diagnosis</subject><subject>Miscellaneous. Technology</subject><subject>Mucin-1 - analysis</subject><subject>Neoplasm Metastasis</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Peritoneal Neoplasms - chemistry</subject><subject>Peritoneal Neoplasms - diagnosis</subject><subject>Pleural Neoplasms - chemistry</subject><subject>Pleural Neoplasms - diagnosis</subject><subject>Receptor, Platelet-Derived Growth Factor beta - analysis</subject><subject>S100 Calcium Binding Protein G - analysis</subject><subject>Thrombomodulin - analysis</subject><subject>Tumor Suppressor Protein p53 - analysis</subject><subject>Vimentin - analysis</subject><issn>0002-9173</issn><issn>1943-7722</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtP3TAQRq2qCC6UX1Cp8qbdBfzIw2aHKC9xJYREq-6sie0QV35A7Czurj-9ibgSq1nM-b7RHIS-UnJGOZHnf7btQyWuW1bJm-3P6rd4Ep_QhsqaV13H2Ge0IYQsS9rxI3Sc819CKBOkPkRHlNZCkI5v0L_7EOaYRpdL0qMNToPHEMHvsss4F-c9HiFjwN4FV6zBU_IWu4jLaLFx8BLTSqYBB_DuJUIsONiclrV3KcAFvlxqZrNbkTK6qVgblwvF9ck4m7-ggwF8tqf7eYJ-3Vw_X91V28fb-6vLbaWZoKVqDZe66TstGy4Ip8C47HtDBBVdy3Xd9LyXsjWM901Tt2x9nUBnpNV2qBnwE_Tjvfd1Sm-zzUUFl7X1HqJNc1YdJW3TMLaA_B3UU8p5soN6nVyAaacoUat4tYpXq3i1iler-CX1bV8_98Gaj8ze9AJ83wOQF8fDBFG7_MHVREraUP4fxPSOVw</recordid><startdate>20010801</startdate><enddate>20010801</enddate><creator>ROBERTS, Fiona</creator><creator>HARPER, Christina M</creator><creator>DOWNIE, Ian</creator><creator>BURNETT, Rodney A</creator><general>American Society of Clinical Pathologists</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010801</creationdate><title>Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: A study of thirteen antibodies</title><author>ROBERTS, Fiona ; HARPER, Christina M ; DOWNIE, Ian ; BURNETT, Rodney A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-6d39c5b7c9538031a239bbd0818763c45b3b996d23b5546200020a7d9ecef42a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adenocarcinoma - chemistry</topic><topic>Adenocarcinoma - diagnosis</topic><topic>Antigens, Surface - analysis</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Calbindin 2</topic><topic>Carcinoembryonic Antigen - analysis</topic><topic>Diagnosis, Differential</topic><topic>Glycoproteins - analysis</topic><topic>Humans</topic><topic>Hyaluronan Receptors - analysis</topic><topic>Immunohistochemistry</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Keratins - analysis</topic><topic>Lewis X Antigen - analysis</topic><topic>Medical sciences</topic><topic>Mesothelioma - chemistry</topic><topic>Mesothelioma - diagnosis</topic><topic>Miscellaneous. Technology</topic><topic>Mucin-1 - analysis</topic><topic>Neoplasm Metastasis</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Peritoneal Neoplasms - chemistry</topic><topic>Peritoneal Neoplasms - diagnosis</topic><topic>Pleural Neoplasms - chemistry</topic><topic>Pleural Neoplasms - diagnosis</topic><topic>Receptor, Platelet-Derived Growth Factor beta - analysis</topic><topic>S100 Calcium Binding Protein G - analysis</topic><topic>Thrombomodulin - analysis</topic><topic>Tumor Suppressor Protein p53 - analysis</topic><topic>Vimentin - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ROBERTS, Fiona</creatorcontrib><creatorcontrib>HARPER, Christina M</creatorcontrib><creatorcontrib>DOWNIE, Ian</creatorcontrib><creatorcontrib>BURNETT, Rodney A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ROBERTS, Fiona</au><au>HARPER, Christina M</au><au>DOWNIE, Ian</au><au>BURNETT, Rodney A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: A study of thirteen antibodies</atitle><jtitle>American journal of clinical pathology</jtitle><addtitle>Am J Clin Pathol</addtitle><date>2001-08-01</date><risdate>2001</risdate><volume>116</volume><issue>2</issue><spage>253</spage><epage>262</epage><pages>253-262</pages><issn>0002-9173</issn><eissn>1943-7722</eissn><coden>AJCPAI</coden><abstract>To identify the most accurate and useful panel to diagnose mesothelioma, we immunostained sections from 112 mesotheliomas, 18 adenocarcinomas, and 11 reactive pleural specimens with 13 antibodies. Positive results for mesotheliomas, adenocarcinomas, and reactive pleura, respectively, were CAM5.2, 111, 18, and 11; vimentin, 30, 3, and 3; HBME-1, 75, 10, and 8; thrombomodulin, 31, 2, and 2; calretinin, 43, 6, and 11; and CD44H, 68, 10, and 4. Positive results for adenocarcinoma markers in mesotheliomas and adenocarcinomas, respectively, were carcinoembryonic antigen, 1 and 15; LeuM1, 7 and 9; and Ber-EP4, 5 and 12. All reactive pleura were negative. Positive results for markers to help distinguish mesothelioma from reactive pleura in mesotheliomas, adenocarcinomas, and reactive pleura, respectively, were epithelial membrane antigen, 76, 17, and 6; p53, 78, 16, and 9; P-170 glycoprotein, 37, 4, and 2; and platelet-derived growth factor receptor beta, 31, 1, and 2. The differential diagnosis of mesothelioma from adenocarcinoma is based on negative markers. Individual mesothelial markers are of low sensitivity and specificity for mesothelioma. However, diagnostic accuracy is improved by the use of antibody panels. To date there are no antibodies that help distinguish mesothelioma from reactive pleura.</abstract><cop>Chicago, IL</cop><pub>American Society of Clinical Pathologists</pub><pmid>11488073</pmid><doi>10.1309/XL6K-8E62-9FLD-V8Q8</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9173 |
| ispartof | American journal of clinical pathology, 2001-08, Vol.116 (2), p.253-262 |
| issn | 0002-9173 1943-7722 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71065522 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adenocarcinoma - chemistry Adenocarcinoma - diagnosis Antigens, Surface - analysis Biological and medical sciences Biomarkers Biomarkers, Tumor - analysis Calbindin 2 Carcinoembryonic Antigen - analysis Diagnosis, Differential Glycoproteins - analysis Humans Hyaluronan Receptors - analysis Immunohistochemistry Investigative techniques, diagnostic techniques (general aspects) Keratins - analysis Lewis X Antigen - analysis Medical sciences Mesothelioma - chemistry Mesothelioma - diagnosis Miscellaneous. Technology Mucin-1 - analysis Neoplasm Metastasis Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Peritoneal Neoplasms - chemistry Peritoneal Neoplasms - diagnosis Pleural Neoplasms - chemistry Pleural Neoplasms - diagnosis Receptor, Platelet-Derived Growth Factor beta - analysis S100 Calcium Binding Protein G - analysis Thrombomodulin - analysis Tumor Suppressor Protein p53 - analysis Vimentin - analysis |
| title | Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: A study of thirteen antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T18%3A28%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunohistochemical%20analysis%20still%20has%20a%20limited%20role%20in%20the%20diagnosis%20of%20malignant%20mesothelioma:%20A%20study%20of%20thirteen%20antibodies&rft.jtitle=American%20journal%20of%20clinical%20pathology&rft.au=ROBERTS,%20Fiona&rft.date=2001-08-01&rft.volume=116&rft.issue=2&rft.spage=253&rft.epage=262&rft.pages=253-262&rft.issn=0002-9173&rft.eissn=1943-7722&rft.coden=AJCPAI&rft_id=info:doi/10.1309/XL6K-8E62-9FLD-V8Q8&rft_dat=%3Cproquest_cross%3E71065522%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71065522&rft_id=info:pmid/11488073&rfr_iscdi=true |